Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors

Classification of neuroendocrine tumors.- Molecular genetics of Pheochromocytoma and paraganglioma.- Molecular Genetics of MEN1-related Neuroendocrine Tumors.- Molecular genetics of  MEN2-related neuroendocrine tumors.- Molecular genetics of Neuroblastoma.- Molecular Genetics of Gastroenteropancreatic Neuroendocrine Tumors.- Current and future radiopharmaceuticals in neuroendocrine tumors imaging.- SPECT/CT, PET/CT and PET/MR: Principles.- Internal dosimetry: Principles and Applications to NET.- Principles and Application of Molecular Imaging for Personalised Medicine and Guiding Interventions in Neuroendocrine Tumors.- Tumor metabolism and metabolomics of pheochromocytomas and paragangliomas.- Radionuclide imaging of pheochromocytoma and paraganglioma in the era of multi-omics.- Radionuclide imaging of Head and neck PGLs.- Radionuclide imaging of Chromaffin cell tumors.- Radionuclide imaging of Gastrointestinal neuroendocrine tumors.- Radionuclide imaging of Pancreatic neuroendocrine tumors.- Radionuclide imaging of Pulmonary, thymic neuroendocrine tumors and other neuroendocrine tumors.- Radionuclide imaging of Medullary thyroid carcinoma.- 131I-MIBG therapy for pheochromocytoma/paraganglioma and neuroblastoma.- Somatostatin receptors-based radionuclide therapy.- Alpha radionuclide therapy: Principles and Applications to NET.- Nanoparticles for Radionuclide Imaging and Therapy: Principles.

Karel Pacak, MD, PhD, DSc, Senior Investigator and Chief, Section on Medical Neuroendocrinology, Professor of Medicine, Eunice Kennedy Shriver NICHD/NIH, Bethesda, MD, USA

David Taieb, MD, PhD, Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France